🟢 Ultragenyx is trading 6.4% up today after reporting record Q2 revenue and a narrowed net loss

Ultragenyx is trading at $27.46 (6.4% up) after reporting record second-quarter revenue of $214 million, which exceeded consensus estimates and narrowed its net loss per share.

• The company reaffirmed its full-year 2026 guidance, highlighting strong performance across its key product portfolio.
• Positive financial results and a narrowed net loss are driving investor optimism and significant after-hours buying interest.